Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma has announced the approval of Loramyc in 13 additional European countries through a mutual recognition procedure with France as reference member state.
Subscribe to our email newsletter
BioAlliance Pharma said that, with this approval to a total of 26 European countries for Loramyc and the recent Setofilm approval in 16 European countries, it is building an attractive cancer supportive care portfolio including the two complementary products.
Dominique Costantini, president and CEO of BioAlliance Pharma, said: “These remarkable achievements for both Loramyc and Setofilm demonstrate BioAlliance Pharma’s expertise and the dedication of its teams. They will contribute to our commercial success in Europe.”
As a preferred partner for hospital-based specialists, BioAlliance Pharma develops and markets products in France, especially in the fields of opportunistic infections and chemotherapy complications.